This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
Following an invitation from Greek authorities, a team of experts from ECDC, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the WHO Regional Office for Europe visited Greece in May 2012.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Following a request by the Romanian government, ECDC conducted a second follow-up country visit to Romania covering HIV, sexually transmitted infections (STIs) and hepatitis B and C from 11–13 May 2011.
Following a request by the Estonian government, ECDC performed a follow-up country visit to Estonia covering HIV and sexually transmitted infections (STIs) from 11–13 October 2010.
Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.
ECDC plays an important role in providing its stakeholders with scientific advice when requested. On 23 September 2010 ECDC received such a request from the European Commission’s DG SANCO (Directorate C – Public Health and Risk Assessment).